The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. This year’s metric has recorded a Price increase of 14.82%. However, over the past six months, we’ve seen a weaker performance of 62.42%. The price of MDGL fallen by 13.96% over the last 30 days. And in the last five days, it has surged by 1.15%.
Madrigal Pharmaceuticals Inc’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $322.67 on 05/01/23, and the lowest price during that time was $119.76, recorded on 10/27/23.
52-week price history of MDGL Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Madrigal Pharmaceuticals Inc’s current trading price is -17.66% away from its 52-week high, while its distance from the 52-week low is 121.84%. The stock’s price range over this timeframe has been between $119.76 and $322.67. The shares of the Healthcare sector company recorded a trading volume of approximately 0.91 million for the day, which was comparatively higher than the average daily volume of 0.54 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Madrigal Pharmaceuticals Inc (MDGL) has experienced a quarterly rise of 12.04% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.29B and boasts a workforce of 376 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 212.76, with a change in price of +139.26. Similarly, Madrigal Pharmaceuticals Inc recorded 502,722 in trading volume during the last 100 days, posting a change of +110.16%.
MDGL’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for MDGL stands at 0.29. Similarly, the long-term debt-to-equity ratio is also 0.29.
MDGL Stock Stochastic Average
Madrigal Pharmaceuticals Inc’s raw stochastic average for the past 50 days is currently at 73.96%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 60.11%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 68.73% and 67.74%, respectively.
